Stopping haemorrhage with Tranexamic acid for hyperacute Onset Presentation including Mobile Stroke Units
Lead PI: Prof Stephen Davis, Prof Geoff Donnan, Dr Henry Zhao & Dr Nawaf Yassi
No. of Patients Currently Recruited: 33 No. of Patients Required: 124
The STOP-MSU trial is a Phase IIa randomised controlled trial investigating use of Tranexamic acid in hyperacute intracerebral haemorrhage (<2hrs onset) with the hypothesis that ultra-early administration may reduce haematoma growth. The primary outcome is ICH growth by 24+/- 3 hours defined by either 33% or 6ml increase from baseline, adjusted from baseline ICH volume.